balapiravir and Hepatitis-C

balapiravir has been researched along with Hepatitis-C* in 2 studies

Other Studies

2 other study(ies) available for balapiravir and Hepatitis-C

Article	Year
Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection. Journal of medicinal chemistry, 2009, Sep-10, Volume: 52, Issue:17 The application of a phosphoramidate prodrug approach to 2'-C-methylcytidine (NM107), the first nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, is reported. 2'-C-Methylcytidine, as its valyl ester prodrug (NM283), was efficacious in reducing the viral load in patients infected with HCV. Several of the phosphoramidates prepared demonstrated a 10- to 200-fold superior potency with respect to the parent nucleoside in the cell-based replicon assay. This is due to higher levels of 2'-C-methylcytidine triphosphate in the cells. These prodrugs are efficiently activated and converted to the triphosphate in hepatocytes of several species. Our SAR studies ultimately led to compounds that gave high levels of NTP in hamster and rat liver after subcutaneous dosing and that were devoid of the toxic phenol moiety usually found in ProTides. Topics: Amides; Animals; Antiviral Agents; Cell Line; Cytidine; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Phosphoric Acids; Polyphosphates; Prodrugs; Structure-Activity Relationship; Virus Replication	2009
High relapse rate seen at week 72 for patients treated with R1626 combination therapy. Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:4 Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Nucleosides; Polyethylene Glycols; Prodrugs; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome	2008

Article

Year

Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.

Journal of medicinal chemistry, 2009, Sep-10, Volume: 52, Issue:17

The application of a phosphoramidate prodrug approach to 2'-C-methylcytidine (NM107), the first nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, is reported. 2'-C-Methylcytidine, as its valyl ester prodrug (NM283), was efficacious in reducing the viral load in patients infected with HCV. Several of the phosphoramidates prepared demonstrated a 10- to 200-fold superior potency with respect to the parent nucleoside in the cell-based replicon assay. This is due to higher levels of 2'-C-methylcytidine triphosphate in the cells. These prodrugs are efficiently activated and converted to the triphosphate in hepatocytes of several species. Our SAR studies ultimately led to compounds that gave high levels of NTP in hamster and rat liver after subcutaneous dosing and that were devoid of the toxic phenol moiety usually found in ProTides.

Topics: Amides; Animals; Antiviral Agents; Cell Line; Cytidine; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Phosphoric Acids; Polyphosphates; Prodrugs; Structure-Activity Relationship; Virus Replication

2009

High relapse rate seen at week 72 for patients treated with R1626 combination therapy.

Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:4

Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Nucleosides; Polyethylene Glycols; Prodrugs; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome

2008